Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC2 | Q13490 | 14/20 | 0.59 |
| ▸ | XIAP | P98170 | 12/20 | 0.59 |
| ▸ | BIRC3 | Q13489 | 10/20 | 0.59 |
| ▸ | BIRC7 | Q96CA5 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24619678 | 0.96 | BIRC2 (0.57) | BIRC2XIAPBIRC3BIRC7 | |
| SCHEMBL28929763 | 0.96 | BIRC2 (0.57) | BIRC2XIAPBIRC3BIRC7 | |
| SCHEMBL24619580 | 0.96 | BIRC2 (0.62) | BIRC2XIAPBIRC3BIRC7 | |
| SCHEMBL24619561 | 0.95 | BIRC2 (0.58) | BIRC2XIAPBIRC3BIRC7 | |
| SCHEMBL28659473 | 0.95 | BIRC2 (0.58) | BIRC2XIAPBIRC3BIRC7 | |
| SCHEMBL29771905 | 0.93 | BIRC2 (0.53) | BIRC2XIAPBIRC3BIRC7 | |
| SCHEMBL24619680 | 0.92 | BIRC2 (0.57) | BIRC2XIAPBIRC3BIRC7 | |
| SCHEMBL24066883 | 0.91 | BIRC2 (0.57) | BIRC2XIAPBIRC3BIRC7 | |
| SCHEMBL20697857 | 0.91 | BIRC2 (0.57) | BIRC2XIAPBIRC3BIRC7 | |
| SCHEMBL24620052 | 0.91 | BIRC2 (0.58) | BIRC2XIAPBIRC3BIRC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220220152-A1 | BIVALENT ANTAGONISTS OF INHIBITORS OF APOPTOSIS PROTEINS | Hepagene Therapeutics (HK) Limited (HK) | 2022-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220220152-A1 | BIVALENT ANTAGONISTS OF INHIBITORS OF APOPTOSIS PROTEINS | BIRC5, BIRC2, BIRC3 | BIRC2 2/4885XIAP 6/4885BIRC3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.